Open Access. Powered by Scholars. Published by Universities.®
Department of Pharmacology and Experimental Therapeutics Faculty Papers
American Society for Blood and Marrow Transplantation Meetings
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
No Evidence Of A Drug-Drug Interaction Between Letermovir (Mk-8228) And Mycophenolate Mofetil, Wl Marshall, C. Badshah, F. Liu, Walter K. Kraft, Md, F. Colon-Gonzalez, A. Van Schanke, Cr. Cho, E. Hulskotte, Jr Butterton, Ee Marcantonio
No Evidence Of A Drug-Drug Interaction Between Letermovir (Mk-8228) And Mycophenolate Mofetil, Wl Marshall, C. Badshah, F. Liu, Walter K. Kraft, Md, F. Colon-Gonzalez, A. Van Schanke, Cr. Cho, E. Hulskotte, Jr Butterton, Ee Marcantonio
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Introduction:
Letermovir (MK-8228) is a potent, oncedaily inhibitor of the cytomegalovirus (CMV) terminase complex that is being developed for the prophylaxis of CMV infection in transplant patients. This study evaluated the pharmacokinetic interactions, safety, and tolerability of letermovir when coadministered in healthy subjects with mycophenolate mofetil (MMF), which is the morpholinoethyl ester prodrug of mycophenolic acid (MPA).
Methods:
This was an open-label trial in 14 healthy female subjects that explored the pharmacokinetic parameters of a single 1 g oral dose of MMF administered alone on Day 1 and coadministered on Day 12 with 480 mg oral once-daily letermovir given on …